Clinical trials: Bevacizumab
NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation
High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
This is a Phase II, single-arm, open-label, multicenter clinical study aimed at evaluating the efficacy and safety of Firmonertinib 160 mg combined with Bevacizumab as neoadjuvant therapy in patients with resectable stage II-IIIB…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma
- Trial name
- HOFIBREN (NCT07182708)
- Testing
- Firmonertinib Mesilate Tablets, Bevacizumab injection
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Peking University Cancer Hospital & Institute
Unresectable Metastatic Rectal Cancer, CAPOX
Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer
To evaluate the efficacy and safety of short-course radiotherapy followed by CAPOX and carrilizumab and bevacizumab or cetuximab in the initial treatment of unresectable metastatic rectal cancer
- Conditions
- Unresectable Metastatic Rectal Cancer, CAPOX, Combination of Radioimmunotherapy
- Trial name
- Union-mRC (NCT07059949)
- Testing
- CAPOX+ Camrelizumab+ Cetuximab, CAPOX+ Camrelizumab+ Bevacizumab
- Volunteers
- 80 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Dynamic Tumor Resistance, Metastatic Colorectal Cancer
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
- Trial name
- NCT07318389
- Testing
- SOC (Standard of care), Bevacizumab, Cetuximab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00096148
- Testing
- idarubicin, cytarabine, bevacizumab
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma
To determine the safety and efficacy of surgical resection with Gliadel® 3.85% wafer implantation, followed by concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide and bevacizumab in…
- Trial name
- KARE004 (NCT00660621)
- Testing
- Temozolomide and Bevacizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Kentuckiana Cancer Institute
Fallopian Tubes Cancer, Ovarian Cancer
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
The immune system of the body has the ability to fight and eliminate infections and cancers. Immune treatments, such as in this study, seek to teach the immune system to find and destroy cancer cells.
- Conditions
- Fallopian Tubes Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT01223235
- Testing
- bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HCC - Hepatocellular Carcinoma, Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
This study is a multicenter retrospective clinical research, led by the First Affiliated Hospital of Wenzhou Medical University, and jointly conducted by other sub-centers.
- Trial name
- NCT07495735
- Testing
- No intervention (observational study)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
This randomized phase II trial studies how well bevacizumab with or without fosbretabulin tromethamine works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity cancer that has come back or is…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01305213
- Testing
- Bevacizumab, Fosbretabulin Tromethamine, Laboratory Biomarker Analysis
- Where
- 51 sites in United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
COVID19 Pneumonia
Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort
Bevacizumab, ZERIBEV® (Pfizer)/AVASTIN® (Roche) 25 mg/ml ®, is a recombinant humanised monoclonal IgG1 antibody It seems interesting to use bevacizumab in severe patients infected with SARS-CoV-2 requiring hospitalization in…
- Trial name
- CORIMMUNO-BEVA (NCT04344782)
- Testing
- Bevacizumab Injection
- Volunteers
- 130 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Salivary Gland Carcinoma, Precision Therapy
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and…
- Trial name
- NCT06145308
- Testing
- Cohort 1 (HER2-positive, RC48-ADC), Cohort 2 (NTRK-fusion or NTRK-mutant), Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Peking Union Medical College
Non-squamous Non-small Cell Lung Cancer
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
The purpose of this study is to test whether the combination of bevacizumab and erlotinib can prolong progression free survival as compared with erlotinib alone as first-line treatment in patients with non small cell lung cancer…
- Trial name
- BEVERLY (NCT02633189)
- Testing
- Erlotinib, Bevacizumab
- Where
- 55 sites in Italy
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute, Naples
Metastatic Colorectal Cancer, pMMR
Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
The main objective of the SIRTCI study is to evaluate the safety and efficacy of the combination chemotherapy (XELOX: Capecitabine plus oxaliplatin), anti-angiogenic (Bevacizumab), SIRT (TheraSphere®) and ICI (Atezolizumab) in…
- Conditions
- Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor
- Trial name
- SIRTCI (NCT04659382)
- Testing
- Atezolizumab, Therasphere, XELOX
- Where
- 19 sites in France
- Volunteers
- 52 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Cancer
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
This is an open-label, multicenter, single-arm, two-stage, Phase Ib study designed to assess the safety, tolerability, and pharmacokinetics of oral cobimetinib with intravenous (IV) atezolizumab and bevacizumab in participants…
- Trial name
- NCT02876224
- Testing
- Atezolizumab, Bevacizumab, Cobimetinib
- Where
- 6 sites in United States, Spain
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Prostate Cancer
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.
- Trial name
- NCT00203424
- Testing
- Erlotinib + Bevacizumab
- Where
- 16 sites in United States
- Volunteers
- 23 people
- Sponsor
- Translational Oncology Research International
Lipid Keratopathy, Penetrating Keratoplasty
Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization
1. Purpose:Our animal study demonstrated the effectiveness of subconjunctival injection of bevacizumab in the inhibition of corneal neovasculization formation.
- Conditions
- Lipid Keratopathy, Penetrating Keratoplasty, Herpetic Keratopathy, Rosacea
- Trial name
- NCT00681603
- Testing
- subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)
- Where
- Taiwan
- Volunteers
- 13 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer
Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer
This study will evaluate the efficacy of weekly paclitaxel-carboplatin combination plus bevacizumab as first line treatment in patients with metastatic triple negative breast cancer.
- Trial name
- NCT00691379
- Testing
- Carboplatin, Bevacizumab, Paclitaxel
- Where
- 11 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
Diabetic Retinopathy
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
This study will provide preliminary data on the dose and dose interval related effects of intravitreally administered Avastin on retinal thickness and visual acuity in subjects with Diabetic Macular Edema (DME) to aid in planning…
- Trial name
- Bevacizumab (NCT00336323)
- Testing
- Laser Photocoagulation, Bevacizumab
- Where
- 34 sites in United States
- Volunteers
- 121 people
- Sponsor
- Jaeb Center for Health Research
Hepatocellular Carcinoma, Portal Hypertension
Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)
The purpose of this study is to discuss the prognostic value of CEPH among HCC patients underwent TACE treatment, its impact on overall survival, and try to stratify patient cohorts for a better treatment strategy.
- Trial name
- NCT05703750
- Testing
- TACE ± Systemic therapy
- Where
- 2 sites in China
- Volunteers
- 228 people
- Sponsor
- Zhongda Hospital
Endometrial Carcinoma
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
The purpose of this study is to find out whether the addition of a drug called Avastin (avastin) to the two-drug combination of carboplatin and paclitaxel shrinks tumors better than the two-drug combination alone in the treatment…
- Trial name
- NCT00879359
- Testing
- carboplatin, paclitaxel, and bevacizumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
ROP Threshold
39946-I Laser and Bevacizumab Treatment for Retinopathy of Prematurity
Retinopathy of prematurity (ROP) is a leading cause of childhood blindness. Vascular endothelium growth factor (VEGF) is an important component of this disease.
- Trial name
- NCT01993043
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Baylor College of Medicine